Publication
Title
Subtractive immunization as a method to develop respiratory syncytial virus (RSV)—specific monoclonal antibodies
Author
Abstract
Respiratory Syncytial Virus (RSV) is a significant cause of lower respiratory tract infections in the young, the elderly, and in immunodeficient patients. As such, the virus represents an important cause of morbidity and mortality worldwide. Development of monoclonal antibodies against RSV has resulted in a commercial prophylaxis, palivizumab (Synagis®), and different antibodies that have improved our understanding of the structure of the viral proteins. In this study, a different immunization technique, subtractive immunization, was evaluated for its applicability to develop RSV-specific antibodies. One hybridoma which produced antibodies with the strongest staining of RSV infected cells, ATAC-0025, was selected for further characterization. This antibody belongs to the IgG1 class, has neutralizing capacity and recognizes the envelope F-protein. The antibody has a broad reactivity against a range of RSV reference strains and clinical isolates.
Language
English
Source (journal)
Antibodies
Publication
2023
ISSN
2073-4468
DOI
10.3390/ANTIB12040062
Volume/pages
12 :4 (2023) , p. 1-12
Article Reference
62
ISI
001130825500001
Pubmed ID
37873859
Medium
E-only publicatie
Full text (Publisher's DOI)
Full text (open access)
UAntwerpen
Faculty/Department
Research group
Project info
Elucidating the role of the Respiratory Syncytial Virus (RSV) peptide p27 and N-glycans in this peptide in protein structure and protective antibody responses.
Identification of host-virus interactions contributing to immunopathology and disease severity in respiratory syncytial virus infections in children.
Highly versatile real-time live cell imaging for infectious disease and inflammation research.
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identifier
Creation 27.10.2023
Last edited 04.11.2024
To cite this reference